ConductScience.org, home

Paper20089952

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L and 11 others. N Engl J Med, 2010. Cited by 2,076 papers, by iCite.

Cite this record

ConductScience Library. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Papers, record 20089952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20089952

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
PubMed
Journal
N Engl J Med
PubMed
Year
2010
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2,076
iCite
Relative citation ratio, by iCite
57.1
iCite
Revised in PubMed
2026-05-18
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kappos LLudwig
2Radue EWErnst-Wilhelm
3O'Connor PPaul
4Polman CChris
5Hohlfeld RReinhard
6Calabresi PPeter
7Selmaj KKrzysztof
8Agoropoulou CCatherine
9Leyk MMalgorzata
10Zhang-Auberson LLixin
11Burtin PPascale
12FREEDOMS Study GroupGroup

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunosuppressive AgentsMajor topic
Multiple Sclerosis, Relapsing-RemittingMajor topic
Propylene GlycolsMajor topic
SphingosineMajor topic
Administration, Oral
Adolescent
Adult
Arrhythmias, Cardiac
Brain
Disability Evaluation
Disease Progression
Double-Blind Method
Female
Fingolimod Hydrochloride
Herpesviridae Infections
Humans
Kaplan-Meier Estimate
Liver Function Tests
Macular Edema
Magnetic Resonance Imaging
Male
Middle Aged
Young Adult

Source PubMed

Download CSV of topics

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00289978Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisDerived from the trialYesClinicalTrials.gov
NCT02939079Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis PatientsBackgroundClinicalTrials.gov
NCT03345940Fingolimod Versus Dimethyl-fumarate in Multiple SclerosisBackgroundClinicalTrials.gov
NCT04088630Fingolimod as a Treatment of Cerebral Edema After Intracerebral HemorrhageBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in20089958Oral therapy for multiple sclerosis--sea change or incremental step?https://conductscience.org/library/papers/20089958PubMed
Comment in20408749
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
https://conductscience.org/library/papers/20408749PubMed
Comment in20445188Oral cladribine and fingolimod for relapsing multiple sclerosis.https://conductscience.org/library/papers/20445188PubMed
Comment in20479024ACP Journal Club. Oral fingolimod was more effective than placebo for relapsing-remitting multiple sclerosis.https://conductscience.org/library/papers/20479024PubMed
Comment in20574638Oral disease-modifying therapies for multiple sclerosis: are we there yet?https://conductscience.org/library/papers/20574638PubMed

Download CSV of comments and corrections

Cited by1,097

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,076 citations.

PMIDTitleJournalYearIn PapersSource
42953005Exploring immune-endothelial interactions in neuroinflammation and vascular dysfunction.Front Mol Neurosci2026https://conductscience.org/library/papers/42953005PubMed
42947850Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical implications.Front Neurol2026https://conductscience.org/library/papers/42947850PubMed
42930009From Global Evidence to Saudi Practice: A Structured Evidence Map of the Diagnosis, Molecular Targets, and Therapeutic Strategies of Multiple Sclerosis in the Kingdom of Saudi Arabia.Diseases2026https://conductscience.org/library/papers/42930009PubMed
42930003Hypertension in People with Multiple Sclerosis: Epidemiology, Mechanisms, Hypertensive Disorders of Pregnancy, and Clinical Implications.Diseases2026https://conductscience.org/library/papers/42930003PubMed
42859599Small Molecule Therapeutic Approaches With a Greater Focus on Hearing Loss: A Review.Health Sci Rep2026https://conductscience.org/library/papers/42859599PubMed
42856682Ocular safety signals of sphingosine-1-phosphate receptor modulators in postmarketing surveillance.Front Pharmacol2026https://conductscience.org/library/papers/42856682PubMed
42847050AI-enabled clinical trials.Nat Rev Bioeng2026https://conductscience.org/library/papers/42847050PubMed
42796323Clinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study.Medicina (Kaunas)2026https://conductscience.org/library/papers/42796323PubMed
42769928Evolving role of CD8+ tissue-resident memory T cells in autoimmune and immune mediated inflammatory diseases: linking pathogenesis to therapeutic approaches.Front Immunol2026https://conductscience.org/library/papers/42769928PubMed
42688580Immunomodulatory and anti-inflammatory potential of S-nitrosoglutathione (GSNO) in multiple sclerosis: a review of mechanisms and therapeutic perspectives.Front Immunol2026https://conductscience.org/library/papers/42688580PubMed
42687918Detection of Lipid-Mediated Diffused Pathological Changes in Multiple Sclerosis.Res Sq2026https://conductscience.org/library/papers/42687918PubMed
42682484Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data.Front Pharmacol2026https://conductscience.org/library/papers/42682484PubMed
42579606Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.Health Technol Assess2026https://conductscience.org/library/papers/42579606PubMed
42548876Association between peripheral blood T cell subsets and clinical disability in multiple sclerosis patients.Front Neurol2026https://conductscience.org/library/papers/42548876PubMed
42474734Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review.J Neurol2026https://conductscience.org/library/papers/42474734PubMed
42462178The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm2026https://conductscience.org/library/papers/42462178PubMed
42432671The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.J Nanobiotechnology2026https://conductscience.org/library/papers/42432671PubMed
42364069Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation.Neurol Ther2026https://conductscience.org/library/papers/42364069PubMed
42329496Tertiary Lymphoid Structure: A Potential Therapeutic Target Affecting Immune Response in Autoimmune Diseases.Clin Rev Allergy Immunol2026https://conductscience.org/library/papers/42329496PubMed
42310690Higher disease reactivation risk in women after fingolimod withdrawal.Acta Neuropathol Commun2026https://conductscience.org/library/papers/42310690PubMed

See all 1,097 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
FINGOLIMODCHEMBL314854Derived from the trial1https://conductscience.org/library/drugs/CHEMBL314854

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20089952

GET https://conductscience.org/api/papers/v1/20089952/cited_by?page=2